Author:
Lund Riikka J.,Huhtinen Kaisa,Salmi Jussi,Rantala Juha,Nguyen Elizabeth V.,Moulder Robert,Goodlett David R.,Lahesmaa Riitta,Carpén Olli
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. Narod, S. Can advanced-stage ovarian cancer be cured? Nat. Rev. Clin. Oncol. 13, 255–261 (2016).
2. Dasari, S. & Tchounwou, P. B. Cisplatin in cancer therapy: molecular mechanisms of action. Eur. J. Pharmacol. 740, 364–378 (2014).
3. Bowtell, D. D. et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer. 15, 668–679 (2015).
4. Galluzzi, L. et al. Systems biology of cisplatin resistance: past, present and future. Cell. Death Dis 5, e1257 (2014).
5. Wei, S. H. et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin. Cancer Res. 8, 2246–2252 (2002).